Static hyperinflation tied to lung cancer risk in COPD

  • Lung Cancer

  • curated by Kelli Whitlock Burton
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Patients with COPD with static lung hyperinflation are >4 times more likely to develop lung cancer as patients with COPD without the disorder.

Why this matters

  • Lung hyperinflation is common in patients with COPD, but there were no data on the association between the disorder and lung cancer risk.
  • Recent studies suggest that COPD increases the risk for lung cancer even after controlling for smoking history.

Study design

  • 848 patients with COPD with 2858 patient-years of follow-up.
  • Funding: Sociedad Madrileña de Neumología y Cirugía Torácica.

Key results

  • At study onset, 39.4% were current smokers and 44.8% were former smokers.
  • Airflow limitation was mild in 14.1%, moderate in 52.2%, severe in 27.1%, and very severe in 6.6%.
  • 2.9% were diagnosed with lung cancer, 88% of whom had NSCLC and 12% SCLC.
  • After multivariable analysis, static hyperinflation, defined by a functional residual capacity greater than 120% predicted, was an independent risk factor for lung cancer (aHR, 4.617; P=.049).
  • Overall, 5.5% were diagnosed with cancer of any origin.
  • Hyperinflation was an independent risk factor for cancer of any origin on univariate analysis, but not multivariable analysis.

Limitations

  • Retrospective, single-center study with an all-white and mostly male cohort.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit